On the other hand, six SNPs found in a prospective, observational genome-wide association study (GWAS) in a cohort of 108 Han Chinese patients with CM who had received fremanezumab or galcanezumab for at least 12 weeks, associated with treatment response with a threshold of p < 1 × 10−7 (rs116870564 in LRRC4C, rs75244870 near ACOX2, rs56216870 near MTSS1, rs12938101 near TMEM92-AS1, rs74655790 in ATAD2B and rs149540851 in OXR1) [28]. This evidence concerns the gene MTSS1 and cutaneous mastocytosis.